Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897163 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL890691 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL7079563 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL6561922 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL3339166 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL14521507 | 1.00 | MEN1 (0.43) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL3805413 | 0.97 | MEN1 (0.41) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL8970405 | 0.97 | MEN1 (0.41) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL8970259 | 0.97 | MEN1 (0.41) | MEN1BLMKMT2APEPDALDH1A1 | |
| SCHEMBL5897097 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-10-02 | — | — | US | disclosed |
| EP-1323827-A2 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-5942644-A | Precursors for the production of chiral vicinal aminoalcohols | BIOCATALYTICS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | HACL2, APEH, HAO2 | MEN1 4553/4885BLM 4704/4885KMT2A 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.